GC024 A Fatigued And Sleepy Patient
A clinical presentation in which persistent fatigue and excessive sleepiness suggest underlying conditions such as obstructive sleep apnea, hypothyroidism, anemia, or other systemic disorders requiring systematic evaluation.
A Fatigued and Sleepy Patient
This lecture, delivered by Prof. Mary Ip (Division of Respiratory Medicine, HKU), is a clinically-driven exploration of why patients present with fatigue and sleepiness, with a laser focus on Obstructive Sleep Apnoea (OSA) as the prototypical sleep-related breathing disorder. It also covers Obesity Hypoventilation Syndrome (OHS) and Central Sleep Apnoea (CSA), including Cheyne-Stokes Respiration (CSR).
How this fits into exams and clinical practice:
- Fatigue/sleepiness is a common chief complaint in primary care, internal medicine, and geriatrics. The lecture teaches you to differentiate the benign (insufficient sleep) from the dangerous (OSA causing cardiovascular disease, driving accidents).
- OSA is a high-yield exam topic because it connects respiratory physiology, cardiology (hypertension, AF, heart failure), endocrinology (metabolic syndrome, hypothyroidism, acromegaly), neurology (stroke), and psychiatry (depression).
- Past papers have tested fatigue differentials, depression screening in fatigue, and respiratory failure — all of which intersect with this lecture. [1]
Key Learning Objectives (from the lecture): [2]
Brief overview of sleep; OSA — pathophysiology, clinical features, diagnostic methods, principles of management, commonly used treatments; Recognise Cheyne-Stokes Respiration and its clinical implications; Recognise Obesity Hypoventilation Syndrome as a clinical entity and its treatment.
1. Sleep Physiology — The Foundation
Sleep is a complex amalgam of physiological and behavioural processes. [2]
Why does this matter? Sleep is not simply "the brain turning off." It is an actively regulated state with distinct EEG patterns, hormonal surges, memory consolidation, and — critically for this lecture — changes in respiratory control.
| Feature | NREM Sleep | REM Sleep |
|---|---|---|
| Mental activity | Decreased mental activities | Active (dreaming) |
| Brain regulation | Brain actively regulatory | Highly active cortex |
| Body | Relatively inactive but movable | Muscle atonia (inhibition of brainstem motor neurons) |
| Eyes | Slow rolling (stage 1) → absent | Bursts of rapid eye movements |
| EEG | Progressive slowing (spindles in N2, delta waves in N3) | Low voltage, mixed frequency (resembles wake) |
| Autonomic | Stable, parasympathetic dominant | Unstable, sympathetic surges |
Why REM muscle atonia matters: If you didn't have atonia during REM, you'd physically act out your dreams (this is exactly what happens in REM Sleep Behaviour Disorder, common in Parkinson's/Lewy body dementia). For OSA, the atonia extends to upper airway dilator muscles → making REM the most vulnerable period for airway collapse.
NREM stages 1 & 2 = light sleep; Stage 3 (& 4) = slow wave sleep / deep sleep. REM sleep = about 20–25% of total sleep time. NREM and REM cycles = about 90–110 minutes each cycle. [2]
Pattern: You cycle through NREM → REM roughly 4–5 times per night. Deep sleep (N3) predominates in the first third of the night; REM predominates in the last third. This is why OSA-related desaturation is often worst in the early morning hours (more REM).
Age, prior sleep history, circadian rhythms, drug ingestion, pathological states. [2]
With advance in age: decrease in total sleep time, deep sleep, and REM sleep; increase in Wake After Sleep Onset (WASO). [2]
Clinical correlation: Elderly patients naturally have more fragmented sleep, less deep sleep, and more awakenings. This makes them more susceptible to daytime fatigue and also makes it harder to distinguish "normal ageing sleep" from pathological sleep disorders.
2. Sleep and Breathing — Why Sleep Unmasks Respiratory Problems
This section is the physiological bridge between normal sleep and OSA. Understanding it explains why diseases like COPD and OSA are worse at night.
Control of breathing involves: respiratory centres, chemical/mechanical/CNS information, respiratory muscles (upper airway muscles, diaphragm, intercostal muscles). [2]
During wakefulness, breathing is maintained by:
- Chemical drive (chemoreceptors sensing CO₂, O₂, pH)
- Behavioural/cortical drive (talking, voluntary hyperventilation)
- Wakefulness drive (reticular activating system keeping respiratory neurons active)
Compared to wakefulness, sleep causes a decrease in minute ventilation (tidal volume × respiratory rate). NREM sleep — decrease in tidal volume and ventilation. REM sleep — breathing pattern unstable and variable in amplitude and frequency, with further decrease in ventilation. [2]
Contributors to decreased ventilation in sleep: [2]
- Decreased muscle contraction from intercostal muscles
- Recumbency with decrease in functional residual capacity (FRC)
- Decreased chemosensitivity to O₂ and CO₂ with decreased ventilatory response to hypoxia and hypercarbia
- Decreased arousal response
First-principles explanation:
- When you lie down, abdominal contents push the diaphragm cephalad → FRC drops → lung bases close → V/Q mismatch worsens.
- During sleep, the "wakefulness drive" to breathe is withdrawn. You rely almost entirely on chemical/automatic drive. If your automatic drive is impaired (central apnoea) or your airway collapses (obstructive apnoea), there is no cortical backup.
- Chemoreceptor sensitivity is blunted during sleep → you tolerate higher CO₂ and lower O₂ before arousing.
In healthy people, during sleep: slight decrease in blood oxygen tension but no decrease in oxygen saturation (Note: Oxygen-Hb dissociation curve); mild increase in blood CO₂ tension but still normal. [2]
The flat portion of the O₂-Hb dissociation curve protects healthy people: even with a small PaO₂ drop, SpO₂ stays near 97–98%.
In diseased states (e.g. COPD, morbid obesity): pre-existing impaired blood gas exchange (e.g. low baseline oxygenation) would worsen during sleep, and further worsens during REM sleep. [2]
Why REM is the Danger Zone
During REM: intercostal muscles are atonic (diaphragm is the only active respiratory muscle), breathing is irregular, and chemosensitivity is at its lowest. If you're already on the steep part of the O₂-Hb dissociation curve (e.g. baseline PaO₂ 65 mmHg in COPD), even a small further PaO₂ drop causes a large SpO₂ fall. This explains nocturnal desaturation in COPD, OHS, and severe OSA.
With abnormal lungs, physiologic breathing changes during sleep may lead to derangement in blood gas exchange (e.g. worse oxygenation during REM sleep in COPD). [2]
Some diseases are more prone to manifest during sleep (may not only be attributed to sleep/wake state per se — may be due to associated changes in posture, temperature, or circadian function):
- Asthma symptoms typically worse at night
- Aspiration occurs in elderly
- Airway secretions accumulate overnight
- Post-nasal drip with cough on lying down
- Pain or medications may disturb sleep [2]
Large group of primary sleep disorders, e.g. insomnia, narcolepsy. Primary sleep-related breathing disorders: sleep apnoea. [2]
The lecture focuses on sleep apnoea but acknowledges the broader family. For exam purposes, know the differential of excessive daytime sleepiness (covered in Section 6 below).
4. Clinical Case — A Man Presenting with Fatigue and Sleepiness
This is the core clinical scenario of the lecture. Every detail is exam-relevant.
M/45, chronic smoker and social drinker. Manager, sedentary lifestyle. c/o feeling fatigued for about 2 years. Further enquiry: actually feels sleepy during "boring" work or difficult to concentrate after lunch (but only rarely dozes off because he was at work). Wife: he would doze off easily on buses or while watching TV. Drives private car on weekends, has "never dozed off" at the wheels, but needs to keep himself awake by loud music if driving longer distances. Has heavy snoring for many years. Weight gain of about 5 kg in past few years. No other constitutional symptoms. Recent health check: BP "borderline" high. [2]
Red Flags in This Case
- Sleepiness while driving (even if he says "never dozed off" — needing loud music to stay awake IS a near-miss). Professional and recreational driving risk must be explicitly assessed.
- Heavy snoring = hallmark of upper airway obstruction.
- Borderline hypertension = may be OSA-related (OSA is a recognized cause of resistant/refractory hypertension).
- Weight gain + sedentary lifestyle = classic OSA risk factor profile.
- "Fatigue" ≠ "Sleepiness" — but this patient's fatigue actually turns out to be sleepiness on careful questioning. Always clarify this distinction.
4.2 History Taking Approach
Ask about sleep pattern: duration of sleep — 6 hours or less on weekdays; quality of sleep, feels refreshed or not, morning headache, daytime naps. [2]
Why this matters: Insufficient sleep is the #1 cause of daytime sleepiness globally. If a patient sleeps only 5–6 hours and their requirement is 7–8 hours, they will be sleepy regardless of OSA. You must establish this before attributing sleepiness to a pathological cause.
Sleep choking; witnessed breathing pauses by wife; features of other sleep disorders. [2]
- Witnessed apnoeas are virtually pathognomonic of OSA (bed partner history is gold).
- Nocturnal choking = the patient's brain arousing them to resume breathing after an apnoeic event.
Careful assessment of "fatigue" — the symptom is non-specific and may be due to many medical conditions. Assessment of daytime sleepiness at various scenarios in daily life (aided by standard questionnaires, e.g. Epworth Sleepiness Scale asking about chance of dozing off in 8 daily activity scenarios). [2]
Epworth Sleepiness Scale (ESS): [3]
| Situation | Score 0–3 |
|---|---|
| Sitting and reading | |
| Watching TV | |
| Sitting inactive in a public space | |
| As passenger in a car for an hour | |
| Lying down to rest during the day | |
| Sitting quietly after lunch without alcohol | |
| In a car while stopped for a few minutes in traffic | |
| Talking to someone |
Normal ≤ 10. Score > 10 suggests pathological sleepiness. [3]
Distinguishing Fatigue from Sleepiness — An Exam Favourite
"Fatigue" is non-specific — it can mean tiredness, lack of energy, weakness, or actual propensity to fall asleep. Always ask:
- "Do you feel sleepy — as in, you could actually fall asleep?" (sleepiness)
- "Do you feel tired/exhausted but couldn't fall asleep even if you tried?" (fatigue without sleepiness)
Sleepiness → think OSA, narcolepsy, insufficient sleep, sedating medications. Fatigue without sleepiness → think anaemia, depression, hypothyroidism, CKD, heart failure, malignancy.
Assess occupational or personal risks due to excessive daytime sleepiness: driving, operation of other mechanical devices, home accidents. [2]
This is medicolegal. In many jurisdictions, physicians have a duty to counsel patients about driving risk if they have untreated OSA with EDS. Document this conversation.
Body habitus — BMI, waist, neck; craniofacial and oropharyngeal features including tonsils; blood pressure and pulse. [2]
| Examination Target | What to Look For | Why |
|---|---|---|
| BMI | > 25 overweight, > 30 obese | Obesity is the strongest modifiable risk factor for OSA |
| Neck circumference | > 40 cm (F), > 43 cm (M) | Neck fat deposits compress pharynx |
| Waist circumference | Central obesity | Metabolic syndrome association |
| Craniofacial | Micrognathia, retrognathia | Small/receding chin narrows pharyngeal space |
| Oropharynx | Mallampati score, tonsillar size, macroglossia | Crowded airway → obstruction |
| Nasal exam | Septal deviation, polyps, congestion | Nasal obstruction worsens OSA |
| BP | Often elevated | OSA causes/worsens hypertension |
| Signs of RHF | Elevated JVP, peripheral oedema, loud P2 | Cor pulmonale in severe OSA/OHS |
| Endocrine signs | Hypothyroid facies, acromegalic features | Secondary causes of OSA [4] |
5. Obstructive Sleep Apnoea (OSA) — In Depth
Sleep apnoea — recurrent episodes of cessation of breathing during sleep. Obstructive — episodic functional occlusion of upper airways due to complete or partial closure of the upper airways. Termination of apnoeas — cerebral arousals (microarousals) with opening of upper airway and thus resumption of airflow. [2]
First-principles pathophysiology: During sleep, pharyngeal dilator muscles (especially genioglossus) lose tone. In a predisposed individual (obesity, narrow airway anatomy), the negative intraluminal pressure generated during inspiration exceeds the ability of these muscles to keep the airway open → airway collapses → airflow stops (apnoea) or is reduced (hypopnoea) → O₂ falls, CO₂ rises → chemoreceptors eventually trigger a microarousal → muscle tone briefly returns → airway reopens with a gasp/snore → patient falls back asleep → cycle repeats.
Sleep itself is associated with decreased muscle tone. In those predisposed to more collapsible upper airway muscles → Obstructive sleep apnoea. [2]
Apnoea — cessation of breathing. Event lasts > 10 seconds. [2]
| Type | Mechanism | Key Feature |
|---|---|---|
| Obstructive apnoea | Complete closure of upper airway ( > 10 seconds) | Chest/abdominal effort present (trying to breathe against closed airway) |
| Central apnoea | Lack of central drive or effector effort to breathe | NO chest/abdominal effort |
| Mixed apnoea | Both central and obstructive components | Starts central → becomes obstructive |
| Hypopnoea | Partial closure of upper airways | Clinically similar outcome to apnoea |
Hence the term Apnoea-Hypopnoea Index (AHI) — numbers of apnoeas and hypopnoeas per sleep hour. OSA is the commonest type of sleep apnoea in the general population. [2]
One person may have a mixed pattern with both obstructive and central apnoeic events (different from the term "mixed apnoea" which refers to one apnoeic event). [2]
Common Exam Trap
Don't confuse "mixed apnoea" (a single event with both central and obstructive phases) with a patient who has "mixed pattern" (both obstructive and central events throughout the night). The exam may test this distinction.
Level 1: Full-lead (usually 16 channels) overnight polysomnogram (PSG), supervised in-laboratory — GOLD STANDARD Level 2: Unattended polysomnogram Level 3: Home study with fewer leads (no EEG) — HSAT (Home Sleep Apnoea Test) Level 4: 1–2 leads (esp. sleep oximetry) for screening and monitoring [2]
| PSG Channel | What It Measures |
|---|---|
| EEG | Sleep stages, cerebral arousals, sleep fragmentation |
| EOG | Eye movements (REM identification) |
| Chin EMG | Muscle tone (REM atonia confirmation) |
| ECG | Cyclical bradytachycardia (vagal during apnoea → sympathetic surge on arousal) |
| Microphone | Snoring |
| Nasal airflow | Airflow across the nose |
| Thoracic & abdominal belts | Chest and abdominal movements (distinguish obstructive from central) |
| Pulse oximetry | Intermittent hypoxia–reoxygenation pattern |
| Body position | Supine-predominant OSA |
| Leg EMG | Leg movements (periodic limb movements) |
Emerging technologies:
Devices not requiring many leads, providing multiple signals, may be used at home, may be disposable. Sleep "wearables" (watches/rings) — not yet ready for diagnosis. [2]
This table is directly from the lecture and is extremely high-yield:
| Category | Risk Factors |
|---|---|
| Well-Defined | Obesity; Male sex (or post-menopause in women); Older age; Craniofacial/upper airway abnormalities (micrognathia, retrognathia) |
| Potential | Smoking (upper airway inflammation, respiratory instability); Family history of snoring/OSA; Nasal congestion; Drugs, alcohol |
| Associated Medical Conditions | Metabolic syndrome, hypertension, diabetes mellitus; Obesity hypoventilation syndrome; Pregnancy (up to 20% by third trimester); End-stage kidney disease; Congestive heart failure, atrial fibrillation, nocturnal dysrhythmias; Chronic lung diseases; Hypothyroidism, acromegaly, polycystic ovary syndrome; Stroke, refractory hypertension |
High Yield: Secondary Causes of OSA
Always think about acromegaly (macroglossia + soft tissue hypertrophy → airway narrowing) and hypothyroidism (myxoedematous tissue deposition in the airway + weight gain) as endocrine causes of OSA. These are commonly examined. [4]
Snoring; Excessive daytime sleepiness (some just c/o being tired); Witnessed apnoeas; Nocturnal choking; Restless sleep; Unrefreshing sleep, morning headache; Irritability, intellectual deterioration, poor concentration; Decreased libido; Enuresis / nocturia. [2]
Why morning headache? CO₂ retention during sleep → cerebral vasodilation → headache on waking. It typically resolves within 30 minutes of waking.
Why nocturia/enuresis? Increased intrathoracic pressure swings during obstructed breathing → increased atrial natriuretic peptide (ANP) release → increased urine production. Nocturia in a middle-aged man should prompt consideration of OSA (not just prostatic disease).
OSA may occur in all age groups. Hong Kong community-based study of middle-aged subjects: OSA (AHI > 5 + EDS) estimated at least 4% of men and 2% of women. Much higher if only AHI is used — up to half of middle-aged men may have AHI > 5. Very high global burden. Prevalence expected to rise with increasing obesity trends. Pathogenesis is multifactorial — lean subjects can still have OSA. [2]
Sleepiness does not correlate very well with the AHI — may miss asymptomatic OSA subjects. [2]
100% have anatomical compromise of variable magnitude (related to obesity or craniofacial factors or both). 36% have poor muscle responsiveness. 36% have unstable respiratory control (high loop gain). 37% have low arousal threshold. [2]
What is "loop gain"? This is a control systems concept. High loop gain means the ventilatory response to a perturbation (e.g. a brief apnoea) is excessive — you overshoot with hyperventilation, which then drives CO₂ too low, which then causes another central pause → perpetuating the cycle. This is more important in central apnoea but contributes to some OSA phenotypes.
What is "low arousal threshold"? Some patients wake up too easily from even minor respiratory events. Paradoxically, this fragments sleep and prevents them from reaching deeper sleep stages where muscle tone might stabilize.
Clinical implication: Not every OSA patient is purely an "anatomy problem." This explains why weight loss alone doesn't cure all OSA, and why some non-obese patients have OSA (craniofacial anatomy, high loop gain, low arousal threshold).
This is one of the most important slides in the lecture. The diagram shows how OSA leads to cardiovascular and metabolic disease:
Hypoxia-reoxygenation → oxidative stress → sympathetic activation → hypertension, insulin resistance, diabetes mellitus; vasoactive mediators, nitric oxide derangement, inflammatory cytokines → endothelial dysfunction → atherosclerotic cardiovascular and cerebrovascular disease. Sleep fragmentation → excessive daytime sleepiness and neurocognitive deficit. [2]
Key mechanistic points:
- Intermittent hypoxia (IH) is the central pathogenic stimulus — it's analogous to repeated ischaemia-reperfusion injury, generating reactive oxygen species.
- Sympathetic activation from arousals + IH → sustained hypertension (including non-dipping nocturnal BP pattern).
- Endothelial dysfunction → accelerated atherosclerosis.
- Metabolic effects: IH → insulin resistance via multiple pathways (HPA axis activation, adipokine dysregulation).
6.1 EDS and AHI — A Complicated Relationship
EDS is a cardinal symptom of OSA. Not all OSA subjects at the same AHI have the same EDS! Some subjects with OSA do not complain of sleepiness (high AHI but low sleepiness score), or vice versa (very sleepy with "mild/moderate" OSA by AHI criteria). [2]
Why? Sleepiness depends not just on AHI but on: degree of sleep fragmentation, hypoxia severity, individual susceptibility, co-existing sleep deprivation, and possibly genetic factors in adenosine receptor sensitivity.
Insufficient sleep! Medications — antihistamines, opioids (analgesics, cough suppressants), sedatives. Disturbance of sleep-wake cycle (e.g. shift work). Central sleep apnoea. Obesity hypoventilation syndrome (usually have concomitant OSA). Narcolepsy. Depression. Periodic leg movement syndrome? Fibromyalgia / Chronic fatigue syndrome. "Idiopathic" hypersomnolence — must rule out other conditions. Many medical conditions can cause "fatigue." [2]
Expanded differential of fatigue (from primary care perspective): [1]
| Category | Examples |
|---|---|
| Sleep-related | Insufficient sleep, OSA, narcolepsy, shift work, insomnia |
| Psychiatric | Depression, anxiety, somatisation |
| Haematological | Iron deficiency anaemia, B12/folate deficiency [5] |
| Endocrine | Hypothyroidism, diabetes mellitus, adrenal insufficiency, hypopituitarism |
| Renal | CKD (uraemia, anaemia of CKD) [6] |
| Cardiac | Heart failure |
| Hepatic | Chronic liver disease |
| Inflammatory/Autoimmune | SLE, RA, PMR |
| Malignancy | Any occult malignancy |
| Medications | Sedatives, beta-blockers, opioids, antihistamines |
| Infections | Chronic infections (TB, HIV, hepatitis) |
2018 Fourth Summative SAQ Q10
"Mr. Lee, 45 years old, comes to your clinic complaining of tiredness. (a) Name four differential diagnoses for fatigue. (b) Name four symptoms to help confirm or exclude your differentials. (c) History taking does not suggest any physical cause — suggest two questions to screen for depression."
Markscheme approach:
- (a) Depression, hypothyroidism, anaemia, OSA (or diabetes, CKD, malignancy)
- (b) Sleep quality/snoring (OSA), mood/anhedonia (depression), cold intolerance/weight gain (hypothyroid), pallor/SOB (anaemia)
- (c) PHQ-2: "Over the past two weeks, have you had little interest or pleasure in doing things?" and "Have you been feeling down, depressed, or hopeless?" [1]
8. OSA and Cardiovascular Disease — Evidence
Controlled for confounding factors, untreated severe OSA have a much higher incidence of fatal or non-fatal cardiovascular events, while OSA treated with CPAP have a much lower incidence (Marin et al., Lancet 2005, 10-year follow-up). [2]
The lecture presents four major RCTs. The key message:
ITT analyses: CPAP did NOT show statistically significant reduction in CVD events in any of the four major RCTs (CERCAS, RICCADSA, SAVE, ISAACC). BUT in CPAP-adherent subgroup analyses: three of four trials (CERCAS, RICCADSA, SAVE) showed statistically significant benefit. [2]
| Trial | Population | Key Finding (ITT) | CPAP Adherent |
|---|---|---|---|
| CERCAS | No prior cardiac disease, non-sleepy | NS (p=0.20) | Significant (p=0.04) |
| RICCADSA | Post-revascularised CAD, non-sleepy | NS (p=0.44) | Significant (p=0.026) |
| SAVE | CAD/cerebrovascular, 63% Asian | NS (p=0.34) | Significant (p=0.02) |
| ISAACC | Post-ACS, non-sleepy | NS (p=0.40) | NS (p=0.76) |
Why ITT failed: All trials enrolled non-sleepy OSA patients (ESS ~5–7) → these patients have less motivation to use CPAP → average CPAP use was only ~3–4 hours/night → inadequate "dose." When you look at those who actually used CPAP adequately (adherent subgroup), benefit appears.
Exam interpretation: There is definite observational evidence but lack of RCT-based evidence for hard CVD endpoint reduction with CPAP. This is an important nuance — the exam might ask you to discuss the evidence base.
RCT evidence for improvement: EDS, health-related quality of life, blood pressure control in hypertension, intermediary outcomes (e.g. endothelial function). [2]
9. Management of OSA
Weight reduction/control — a "must" advice for those who are overweight/obese. Sleep hygiene — e.g. adequate sleep hours (most people need 7–8 hours), otherwise may still be sleepy despite adequately treating OSA. [2]
Correlation between AHI and BMI, though obesity only accounts for 60% of AHI variance (younger adults). Reduction in body weight can improve OSA AND directly benefit obesity-related cardiometabolic diseases. CPAP treatment per se does NOT reduce body weight. [2]
Management of obesity: lifestyle behavioural modification, anti-obesity medications, bariatric surgery. [2]
9.3 Interventional Treatment
Provides positive pressure via a nasal mask (or other interface) and acts as a "pneumatic splint" to prevent collapse/closure of upper airways. Highly efficacious for abolishing obstructive events. Needs to be adherent (compliant) to CPAP use. [2]
How CPAP works (first principles): The positive pressure (typically 5–20 cmH₂O) exceeds the collapsing pressure of the upper airway → keeps it open → eliminates apnoeas/hypopnoeas → normalises oxygenation → eliminates arousals → restores normal sleep architecture → resolves EDS.
Adherence is the Achilles heel. Many patients find CPAP uncomfortable (mask leak, claustrophobia, nasal congestion, aerophagia). Adequate use is generally defined as ≥ 4 hours/night on ≥ 70% of nights, but more is better.
Worn during sleep to push mandible forwards and improve upper airway muscle tone. Variable and often incomplete efficacy, mainly for those with only moderate degree of OSA. [2]
Different types of surgery. Only for highly selected subjects. Variable efficacy, few long-term data — body weight increase or ageing with time. Tonsillectomy in adults uncommonly indicated. [2]
Surgical options include uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation. MMA has better evidence but is a major procedure.
1) Target obesity — new and more effective anti-obesity drugs available (e.g. GLP-1 receptor agonists like semaglutide/tirzepatide). 2) Target other OSA pathogenetic mechanisms, e.g. UA muscle tone, unstable respiratory control, arousal threshold (still in research stage). [2]
Sleep positioning (lateral sleep for supine-predominant OSA), neurostimulation (hypoglossal nerve stimulation), bariatric surgery for obesity, treat nasal obstruction, myofunctional training. [2]
| Treatment | Best For | Efficacy | Key Limitation |
|---|---|---|---|
| CPAP | All severities; first-line for moderate-severe | Highly efficacious | Adherence |
| Mandibular advancement device | Mild-moderate OSA, CPAP intolerant | Variable, often incomplete | Less effective than CPAP |
| Weight loss | All overweight/obese OSA patients | Improves AHI; may cure mild OSA | Hard to maintain; doesn't cure all OSA |
| Surgery (UPPP) | Selected patients | Variable; often incomplete | Invasive; long-term data lacking |
| Positional therapy | Supine-predominant OSA | Useful adjunct | Limited to specific phenotype |
| Anti-obesity drugs | Obese OSA | Promising (GLP-1 agonists) | Still emerging evidence for OSA-specific outcomes |
Indications of treatment: based on both degree of AHI severity AND symptoms, and other concurrent risk factors. [2]
In practice:
- Severe OSA (AHI ≥ 30): Treat regardless of symptoms (cardiovascular risk).
- Moderate OSA (AHI 15–29): Treat if symptomatic (EDS, impaired QoL, occupational risk) or significant comorbidities.
- Mild OSA (AHI 5–14): Treat if symptomatic; otherwise, conservative measures + monitoring.
Residual high degree of sleepiness after OSA treatment: Check treatment adherence (e.g. some only use CPAP for 2 hours out of 7 hours sleep). Look for other concurrent causes of EDS (e.g. sleep deprivation, insufficient sleep). [2]
Occurs in those with gross obesity. "Hypoventilation" and many also have OSA. Hypoventilation evidenced by high daytime pCO₂. Chronic type 2 respiratory failure (may present as acute-on-chronic respiratory failure with CO₂ narcosis). Right heart failure (cor pulmonale). Acute stage — respiratory failure responds well to non-invasive ventilatory support. Long-term — home use of nasal Bi-level PAP or nCPAP, reduce obesity. [2]
Definition: OHS = obesity (BMI ≥ 30) + daytime hypercapnia (PaCO₂ > 45 mmHg) + no other cause of hypoventilation (e.g. COPD, neuromuscular disease, chest wall deformity).
"The Pickwickian Syndrome" — named after Joe, the fat boy in Dickens' The Pickwick Papers who was always falling asleep. [2]
Pathophysiology: Obesity → increased work of breathing (heavy chest wall, elevated diaphragm) + reduced respiratory compliance + decreased central chemosensitivity to CO₂ (possibly leptin resistance) → chronic hypoventilation → CO₂ retention → metabolic compensation (renal HCO₃⁻ retention) → further blunting of central drive → vicious cycle. Most OHS patients (~90%) also have concomitant OSA.
Treatment:
- Acute: Non-invasive ventilation (NIV) — Bi-level PAP (BiPAP) with backup rate
- Long-term: Home NIV (BiPAP or CPAP if predominantly OSA), weight reduction (bariatric surgery may be definitive)
OHS vs. Pure OSA — Key Distinction
- OSA: Normal daytime blood gases. Pathology is purely during sleep (intermittent upper airway obstruction).
- OHS: Abnormal daytime blood gases (elevated PaCO₂). This is type 2 respiratory failure. More severe, more dangerous, more likely to present with acute decompensation.
- An ABG showing compensated respiratory acidosis (high PaCO₂, high HCO₃⁻, near-normal pH) in an obese patient should make you think OHS.
Defect in: central control — lack of respiratory drive, e.g. part of Cheyne-Stokes Respiration (CSR-CSA) in heart failure, or CSA due to drugs such as opioids. Efferent limb — no respiratory muscle contraction, e.g. neuromuscular junction (myasthenia gravis), muscular diseases (muscular dystrophy). Result: lack of any "effort" or "effective effort" of breathing. [2]
Key distinction from OSA: In CSA, the airway is not obstructed — the brain simply fails to send the signal to breathe, or the muscles cannot execute the signal. On PSG, there is no chest/abdominal effort during central apnoeic events (contrast with OSA where effort is present but airflow is absent).
11.1 Cheyne-Stokes Respiration (CSR)
One characteristic form of breathing — wax and wane pattern, may have central apnoea (CSR-CSA) at the end of the waning phase. Usually associated with heart failure, atrial fibrillation, or stroke. CSR associated with worse prognosis in heart failure. CSR is likely caused by heart failure with circulatory slowing, and may disappear if heart failure is controlled. Does CSR aggravate heart failure? Some form of PAP device to correct CSR — but will this lead to better health outcomes such as improved heart failure? [2]
First-principles explanation of CSR: In severe heart failure, circulation time is prolonged (blood takes longer to travel from lungs to brain). This creates a delay in chemoreceptor feedback. When the patient breathes more (e.g. triggered by a slight rise in CO₂), the resulting drop in CO₂ doesn't reach the brainstem for several seconds → the system overshoots → hyperventilation drives CO₂ below the apnoeic threshold → breathing stops (central apnoea) → CO₂ rises again → but the brainstem doesn't detect it immediately due to circulatory delay → eventually responds with hyperventilation → crescendo-decrescendo pattern.
Clinical recognition: The waxing-waning breathing pattern is observable at the bedside. Family members may describe it. On PSG, it produces a characteristic periodic pattern of central apnoeas alternating with crescendo-decrescendo hyperpnoea.
Treatment: Optimise heart failure treatment first (diuretics, ACEI/ARB, beta-blockers, MRA). The SERVE-HF trial (adaptive servo-ventilation for CSR-CSA in HFrEF) showed increased mortality in the treatment group → ASV is now contraindicated in HFrEF with CSR. Supplemental O₂ may help.
| Related Topic | Connection |
|---|---|
| Respiratory failure (GC 023) | OHS presents as type 2 respiratory failure. COPD patients have worsened blood gases during sleep, especially REM. |
| Heart failure (GC 084) | CSR-CSA in heart failure. OSA is a risk factor for AF and HF. |
| Anaemia (GC 076) | Fatigue differential. Anaemia causes fatigue without sleepiness. [5] |
| DM / Metabolic syndrome (GC 078) | OSA → insulin resistance → DM. Metabolic syndrome is associated with OSA. |
| Syncope / arrhythmia (GC 089) | Nocturnal dysrhythmias (bradytachycardia) in OSA. AF association. |
| Geriatric assessment (GC 038, 054) | Sleep changes with ageing. Falls risk from daytime sleepiness. Polypharmacy causing sedation. |
| Psychiatric conditions (GC 017, 167, CFB PSY03) | Depression causes fatigue. Insomnia in anxiety. Sedating psychotropics. |
| Pituitary tumours / Acromegaly | Acromegaly → OSA via macroglossia and soft tissue hypertrophy. [4] |
| Hypothyroidism | Hypothyroidism → OSA (myxoedematous tissue, weight gain). Also causes fatigue independently. |
| Prescribing in older people (GC 079) | Sedating medications (opioids, benzodiazepines, antihistamines) worsen OSA and cause daytime sleepiness. |
13. Likely Exam Questions
-
"A 50-year-old obese man presents with excessive daytime sleepiness and loud snoring. His wife reports witnessed apnoeas. BP 155/95. (a) What is the most likely diagnosis? (b) Name 3 risk factors in this patient. (c) What investigation would you request? (d) Describe the first-line treatment."
- (a) Obstructive sleep apnoea
- (b) Obesity, male sex, hypertension (also: age, smoking if applicable)
- (c) Overnight polysomnography (PSG) — gold standard; or home sleep apnoea test (HSAT)
- (d) Nasal CPAP (pneumatic splint to prevent upper airway collapse) + weight reduction advice + sleep hygiene
-
"Define the AHI and state the severity classification of OSA."
- AHI = number of apnoeas and hypopnoeas per hour of sleep
- No OSA: < 5; Mild: 5–< 15; Moderate: 15–< 30; Severe: ≥ 30
-
"Describe the pathophysiological cascade by which OSA leads to cardiovascular disease."
- Intermittent hypoxia-reoxygenation → oxidative stress → sympathetic activation → hypertension; inflammatory cytokines + endothelial dysfunction → atherosclerosis → CVD/stroke; sleep fragmentation → EDS/neurocognitive deficit; intrathoracic pressure swings → cardiac preload/afterload changes → heart failure
-
"A morbidly obese patient presents with somnolence, cyanosis, and peripheral oedema. ABG shows pH 7.32, PaCO₂ 58, PaO₂ 52, HCO₃⁻ 34. What is the diagnosis? How would you manage acutely?"
- Obesity Hypoventilation Syndrome (Pickwickian Syndrome) with acute-on-chronic type 2 respiratory failure and cor pulmonale
- Acute: Non-invasive ventilation (BiPAP); Long-term: home NIV + weight reduction (consider bariatric surgery)
-
"What is Cheyne-Stokes respiration? Name 3 associated conditions."
- Waxing-waning breathing pattern with periodic central apnoeas; associated with heart failure, atrial fibrillation, stroke
| Trap | Correct Answer | Why Students Get It Wrong |
|---|---|---|
| CPAP reduces body weight in OSA | FALSE — CPAP does NOT reduce weight | Students assume treating the disease treats the cause |
| All patients with AHI > 5 are symptomatic | FALSE — many are asymptomatic | EDS does not correlate well with AHI |
| ASV is the treatment for CSR-CSA in HFrEF | FALSE — ASV is contraindicated (SERVE-HF trial) | Students remember "treat the apnoea" but forget the trial outcome |
| Level 4 sleep study is sufficient for diagnosis | FALSE — Level 4 (oximetry alone) is for screening, not definitive diagnosis | Confused with Level 1 (PSG) |
| Lean people cannot have OSA | FALSE — craniofacial anatomy, high loop gain, low arousal threshold | Obesity is the strongest risk factor but not the only one |
High Yield Summary
- Sleep physiology: NREM (stages N1–N3) + REM; cycles of 90–110 min; REM = 20–25% of sleep; ageing decreases deep sleep and increases WASO.
- Sleep reduces ventilation via decreased muscle tone, decreased FRC (recumbency), decreased chemosensitivity, and loss of wakefulness drive. In diseased lungs, this causes significant hypoxia especially during REM.
- OSA = recurrent upper airway collapse during sleep → apnoeas/hypopnoeas → intermittent hypoxia + sleep fragmentation → EDS + cardiovascular/metabolic consequences.
- AHI = apnoeas + hypopnoeas per sleep hour; normal < 5; mild 5–< 15; moderate 15–< 30; severe ≥ 30.
- Gold standard diagnosis: Level 1 in-lab polysomnography.
- Risk factors: Obesity (strongest), male sex, age, craniofacial abnormalities, smoking, hypothyroidism, acromegaly.
- Symptoms: Snoring, EDS, witnessed apnoeas, nocturnal choking, morning headache, nocturia, decreased libido.
- OSA cascade: Intermittent hypoxia → oxidative stress → sympathetic activation → HTN, DM, atherosclerosis, endothelial dysfunction.
- Treatment: CPAP (first-line, pneumatic splint), weight loss (essential), oral appliances (moderate OSA), surgery (selected), anti-obesity drugs (emerging).
- OHS = obesity + daytime hypercapnia + no other cause. Type 2 respiratory failure, cor pulmonale. Treat with NIV + weight reduction.
- CSA/CSR: Central apnoea from impaired drive (heart failure, opioids) or effector failure (NMJ/muscle disease). CSR = wax-wane pattern in heart failure. Treat the underlying cause; ASV contraindicated in HFrEF.
- Always differentiate fatigue from sleepiness. Fatigue is non-specific (anaemia, depression, CKD, hypothyroidism, malignancy, etc.). Sleepiness implies propensity to fall asleep (OSA, narcolepsy, insufficient sleep, medications).
Active Recall - A Fatigued and Sleepy Patient
[1] Past papers: 2018 Fourth Summative SAQ (Q10 — fatigue differentials and depression screening) [2] Lecture slides: GC 024. A Fatigued and Sleepy Patient.pdf (all pages) [3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Epworth Sleepiness Scale, history taking for OSA) [4] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf (acromegaly and OSA); Block A - Introduction to Endocrine investigations.pdf (acromegaly facial features and OSA) [5] Lecture slides: GC 076. Pallor_diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf; Senior notes: Block A - Pallor_ diagnosis of anaemia (chronic anaemia presenting with fatigue) [6] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (fatigue as symptom of CKD)
GC023 A Cyanotic, Dyspneic Elderly Man: Respiratory Failure
Respiratory failure is a condition in which the respiratory system fails to maintain adequate gas exchange, resulting in hypoxemia with or without hypercapnia, often presenting with cyanosis and dyspnea, particularly in elderly patients with compromised cardiopulmonary reserve.
GC025 A Jaundiced And Incoherent Patient Liver Failure
Liver failure is a severe deterioration of hepatic function resulting in jaundice, hepatic encephalopathy (manifesting as confusion and incoherence), coagulopathy, and potential multiorgan dysfunction due to the liver's inability to perform its synthetic, metabolic, and detoxification functions.